Guardian Pharmacy Services, Inc. (GRDN)
Consumer Cyclical › Retail-Drug Stores and Proprietary Stores
Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Piotroski F-Score 5/9 — moderate financial health
- Loss-making — negative ROE of -47.9%
- Revenue growing at 18% annually
Guardian Pharmacy Services, Inc. (GRDN) is a Consumer Cyclical company operating in Retail-Drug Stores and Proprietary Stores, listed on the NYSE . Key value metrics: Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Guardian Pharmacy Services, Inc. — Fundamental Analysis Summary
On financial health, GRDN shows a moderate Piotroski F-Score of 5/9, and negative return on equity of -47.9% (sector average: 1.7%), and manageable leverage with a debt-to-equity ratio of 1.00.
StockPik's composite Value Score for GRDN is 52/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
GRDN reports a thin gross margin of 19.6% (sector average: -36.6%) and a negative operating margin of -4.6%.
GRDN shows revenue growing at 18% year-over-year, with earnings growing at 145%.